source
- Servier’s $1.55 billion Becker muscular dystrophy drug fails pivotal Phase 3 trialServier announced that its experimental drug for Becker muscular dystrophy did not meet its primary endpoint in a Phase 3 trial called GRAND CANYON. The drug, sevasemten, was acquired from Edgewis…
- T-Therapeutics secures $133M Series B to advance TCR-CD3 bispecifics with major pharma investorsT-Therapeutics announced a $133 million Series B financing round backed by several of the world’s largest drug developers, including Eli Lilly, Johnson & Johnson, Merck KGaA and Sanofi, along with…